{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:04:10Z","timestamp":1790291050918,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:p>PURPOSE: To investigate the effect of recombinant human erythropoietin (epoetin beta) on anemia, transfusion need, and quality of life (QOL) in severely anemic patients with low-grade non-Hodgkin\u2019s lymphoma (NHL), chronic lymphocytic leukemia (CLL), or multiple myeloma (MM).<\/jats:p>\n                  <jats:p>PATIENTS AND METHODS: Transfusion-dependent patients with NHL (n = 106), CLL (n = 126), or MM (n = 117) and a low serum erythropoietin concentration were randomized to receive epoetin beta 150 IU\/kg or placebo subcutaneously three times a week for 16 weeks. Primary efficacy criteria were transfusion-free and transfusion- and severe anemia\u2013free survival (hemoglobin [Hb] &gt; 8.5 g\/dL) between weeks 5 to 16. Response was defined as an increase in Hb \u2265 2 g\/dL with elimination of transfusion need. QOL was assessed by the Functional Assessment of Cancer Therapy scale.<\/jats:p>\n                  <jats:p>\n                    RESULTS: Transfusion-free (P = .0012) survival and transfusion- and severe anemia\u2013free survival (P = .0001) were significantly greater in the epoetin beta group versus placebo (Wald \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    test), giving a relative risk reduction of 43% and 51%, respectively. The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P &lt; .0001). After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P &lt; .05); this improvement correlated with an increase in Hb concentration (\u2265 2 g\/dL). A target Hb that could be generally recommended could not be identified.\n                  <\/jats:p>\n                  <jats:p>CONCLUSION: Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.<\/jats:p>","DOI":"10.1200\/jco.2002.08.131","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:13:48Z","timestamp":1027761228000},"page":"2486-2494","source":"Crossref","is-referenced-by-count":232,"title":["Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies"],"prefix":"10.1200","volume":"20","author":[{"given":"A.","family":"\u00d6sterborg","sequence":"first","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Brandberg","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Molostova","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Iosava","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Abdulkadyrov","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hedenus","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Messinger","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology and Hematology, Karolinska Hospital, Stockholm, Sweden; Far-East Medical Center, Khabarovsk, and Research Institute of Hematology and Transfusiology, St Petersburg, Russia; Institute for Hematology and Transfusiology, Tblisi, Georgia; Sundsvall Hospital, Sundsvall, and Sweden; and F. Hoffmann-La Roche Ltd, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-108227","unstructured":"Kyle  RA:   Multiple myeloma:  Review of 869 cases.   Mayo Clin Proc 50:  29,1975-40,"},{"key":"R2-108227","doi-asserted-by":"publisher","DOI":"10.1159\/000203625"},{"key":"R4-108227","unstructured":"Thomas  ML:   Impact of anemia and fatigue on quality of life in cancer patients:  A brief review.   Med Oncol 15:  S3,1998-S7,     (suppl)"},{"key":"R5-108227","unstructured":"Cella  D:   Factors influencing quality of life in cancer patients:  Anemia and fatigue.   Semin Oncol 25:  43,1998-46,    (3 suppl 7)"},{"key":"R6-108227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222402"},{"key":"R7-108227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446"},{"key":"R8-108227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675"},{"key":"R9-108227","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"R10-108227","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"R11-108227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R12-108227","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"R13-108227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219"},{"key":"R14-108227","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433915"},{"key":"R15-108227","unstructured":"Cleeland  CS,   Demetri  GD,   Glaspy  J,  et al:  Identifying hemoglobin level for optimal quality of life:  Results of an incremental analysis.   Proc Am Soc Clin Oncol 18:  574a,1999  (abstr)"},{"key":"R16-108227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.6.1676.bloodjournal8561676"},{"key":"R17-108227","unstructured":"Cazzola  M,   Ponchio  L,   Pedrotti  C,  et al:  Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.  Haematologica 81:  434,1996-441,"},{"key":"R18-108227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1056.1056"},{"key":"R19-108227","unstructured":"\u00d6sterborg  A:   Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anemia:  What have we learned?   Med Oncol 15:  S47,1998-S49,     (suppl 1)"},{"key":"R20-108227","unstructured":"Sunder-Plassmann  G,   Horl  WH:   Importance of iron supply for erythropoietin therapy.  Nephrol Dial Transplant 10:  2070,1995-2076,"},{"key":"R21-108227","unstructured":"Glaspy  J,   Cavill  I:   Role of iron in optimizing responses of anemic cancer patients to erythropoietin.  Oncology 13:  461,1999-473,"},{"key":"R22-108227","unstructured":"Brandberg  Y:   Assessing the impact of cancer-related anaemia on quality of life and the role of rHuEPO.  Med Oncol 17:  S23,2000-S31,     (suppl 1)"},{"key":"R23-108227","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3412"},{"key":"R24-108227","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2865"},{"key":"R25-108227","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"R26-108227","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.434"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.08.131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:36:41Z","timestamp":1653496601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.08.131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,15]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"alternative-id":["10.1200\/JCO.2002.08.131"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.08.131","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,15]]}}}